Literature DB >> 8195960

Changing trends in the management of retinoblastoma: 1951-1965 vs 1966-1980.

D H Abramson1, K Niksarli, R M Ellsworth, C A Servodidio.   

Abstract

A retrospective analysis of the records of 1253 retinoblastoma patients (567 females, 665 males, and sex of one unknown) seen in the years 1951-1965 (575 patients, Interval I) and 1966-1980 (678 patients, Interval II) was conducted to determine changes in the manner of presentation of the disease, the treatment modalities employed, and their subsequent outcomes following treatment. There was no significant difference between the two 15-year time intervals in the age at presentation (mean, range), laterality, gender, family history, laterality vs gender distribution, family history vs laterality, employment of chemotherapy in unilateral cases or the use of external beam radiation (EBR) in bilateral cases. Changing trends in the management of retinoblastoma were observed as a result of the introduction of new treatment modalities, such as cryotherapy, light coagulation, and radioactive plaque therapy. Bilateral patients have received chemotherapy less frequently in interval II. The use of photocoagulation, cryotherapy, and brachytherapy for bilaterals, and cryotherapy for unilaterals increased significantly during Interval II. During both time intervals, a significantly higher percentage of unilaterally affected eyes were enucleated compared with bilaterally affected eyes; in addition, there was a decrease in the percentage of enucleations performed on both unilaterally and bilaterally affected eyes. In Interval II, 87% of unilateral patients and 91% of the bilateral patients had an enucleation performed.

Entities:  

Mesh:

Year:  1994        PMID: 8195960     DOI: 10.3928/0191-3913-19940101-07

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  12 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Retinoblastoma--trends in conservative management.

Authors:  J Dudgeon
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

3.  Histopathologic grading of anaplasia in retinoblastoma.

Authors:  Pia R Mendoza; Charles S Specht; G Baker Hubbard; Jill R Wells; Michael J Lynn; Qing Zhang; Jun Kong; Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

4.  Presentation of retinoblastoma at a paediatric eye clinic in ghana.

Authors:  V Essuman; C T Ntim-Amponsah; S Akafo; L Renner; L Edusei
Journal:  Ghana Med J       Date:  2010-03

Review 5.  Retinoblastoma: An overview.

Authors:  Achyut N Pandey
Journal:  Saudi J Ophthalmol       Date:  2013-11-21

6.  Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma.

Authors:  Marco A Ramírez-Ortiz; M Veronica Ponce-Castañeda; M Lourdes Cabrera-Muñoz; Aurora Medina-Sansón; Xinhua Liu; Manuela A Orjuela
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

7.  Orbital retinoblastoma: Present status and future challenges - A review.

Authors:  Mohammad J Ali; Santosh G Honavar; Vijay A P Reddy
Journal:  Saudi J Ophthalmol       Date:  2010-10-13

8.  Clinical results of chemotherapy based treatment in retinoblastoma patients: a single center experience.

Authors:  Hyery Kim; Ji Won Lee; Hyoung Jin Kang; Hyeon Jin Park; Yoon Yi Kim; Hee Young Shin; Young Suk Yu; Il Han Kim; Hyo Seop Ahn
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

9.  Molecular pathology of retinoblastoma.

Authors:  Mallikarjuna Kandalam; Moutushy Mitra; Krishnakumar Subramanian; Jyotirmay Biswas
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 10.  Risk definition and management strategies in retinoblastoma: current perspectives.

Authors:  Fariba Ghassemi; Alireza Khodabande
Journal:  Clin Ophthalmol       Date:  2015-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.